[DTIC: effect on fibrinolysis and thrombocyte function].
Pathogenesis of Budd-Chiari-syndrome, under treatment e.g. of malignant melanoma with DTIC (dacarbacin) is still unknown. In our investigations we could not find any hint for the hypothesis that Budd-Chiari-syndrome under DTIC is caused by hemostaseological impairment.
D001780:Blood Coagulation Tests; D006502:Budd-Chiari Syndrome / Q000139:chemically induced*; D003606:Dacarbazine / Q000009:adverse effects* / Q000627:therapeutic use; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D010974:Platelet Aggregation / Q000187:drug effects*; D010976:Platelet Count / Q000187:drug effects; D012878:Skin Neoplasms / Q000188:drug therapy*
D003606:Dacarbazine
DTIC: Einfluss auf Fibrinolyse und Thrombozytenfunktion.